ClinicalTrials.gg
CompletedNCT05760261Updated Jan 16, 2025

Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years

A Phase 1 interventional study of Midazolam and GSK3882347 in Urinary Tract Infections, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Urinary Tract Infections by GlaxoSmithKline — 4 open to participants now, 4 under way, none of them phase 3. Urinary Tract Infections · GlaxoSmithKline.

Enrollment
8th of 13
27 · median 61
Started
2023
with 1 other
Phase 1
5 of 14
2 open now
Registered
9th of 14
by date

Among the 14 studies in Urinary Tract Infections by GlaxoSmithKline, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 1, and was the 9th registered.

Urinary Tract Infections

804 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

4 of the 14 studies in Urinary Tract Infections by GlaxoSmithKline are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Urinary Tract Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The objective of this study is to determine the magnitude and clinical relevance of a potential drug-drug interaction of GSK3882347 with midazolam (MDZ) in healthy participants. This study assesses the effect of GSK3882347 as an inducer of Cytochrome P450 3A4 (CYP3A4) using MDZ, a sensitive substrate of hepatic and intestinal CYP3A4. The study will investigate MDZ pharmacokinetic (PK) effect in two dosing periods:

Period 1: A single dose of MDZ Period 2: 14-days of once daily repeat dosing of GSK3882347 followed by single dose of MDZ co-administered with GSK3882347 on Day 15 (14-days has been selected as this duration is required in order to maximize any potential CYP3A4 enzyme induction).

03

Conditions studied

  • Urinary Tract Infections

Keywords

  • Drug-drug interaction
  • Cytochrome P450 3A4 (CYP3A4)
  • 1-hydroxymidazolam
  • Hormonal contraceptive agent
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. A participant with a clinical abnormality or laboratory parameter(s) not specifically listed in the exclusion or exclusion criteria that is outside the reference range for the population being studied may be included only if the investigator, in consultation with the Medical Monitor (if required), agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Body weight at least 50.0 kilogram (kg) (110 pound [lbs.]) for males and 45.0 kg (99 lbs.) for females; and (BMI) within the range 18.5 - 32.0 kg per meter square (kg/m\^2) (inclusive).
  • Male participants are eligible to participate if they agree to the following during the study intervention Period and for at least 3 days, after the last dose of study intervention:

    • Refrain from donating fresh unwashed semen

Plus, either:

  • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.

OR

  • Must agree to use /barrier.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

    • Is a woman of non- (WONCBP) . OR
    • Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of lesser than (\<) 1 percent (%).
  • A WOCBP must have a negative highly sensitive pregnancy test [urine or serum] as required by local regulations) within 24h before the first dose of study intervention.
  • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).

Exclusion criteria

Exclusion Criteria:

  • History or presence of significant cardiovascular, respiratory, hepatic, renal, urological, gastrointestinal, metabolic, endocrinological, hematological, immunologic, dermatologic, neurological or psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data or in the opinion of the investigator places the participants at unacceptable risk or would make adhering to study procedures for the duration of the study difficult. Participants who have had a gastric bypass or a cholecystectomy are excluded from the study.
  • Abnormal blood pressure, as determined by the investigator.
  • Alanine transferase () value greater than (>)1.5 × (ULN).
  • value >1.5 × ULN (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • The participant has a current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • The participant has congenital long syndrome or known prolongation of the corrected QT (QTc) interval.
  • The participant has any history of heart failure.
  • The participant has a family history of QT prolongation or sudden death.
  • The participant has any current or previous a history of episodes of symptomatic bradycardia or bradyarrhythmia.
  • The participant has a QTc >450 millisecond (msec). Note: The QTc is the QT interval corrected for heart rate according to Fridericia formula, machine, or manual overread.

    11. The participant has anuria, oliguria, or impairment of renal function ( by Modification of diet in renal disease [MDRD] \<90 milliliter per minute per 1.73 meter square [mL/min/1.73m\^2] or serum creatinine > ULN or urine albumin-creatinine ratio [ACR] of ≥300 milligram per gram [mg/g] at screening).

  • The participant must agree to and adhere to the concomitant therapy (including nondrug therapies) restrictions from the Screening Visit through to the end of the end of the study (including telephone visit).
  • Participation in the study would result in loss of blood or blood products in excess of 500 milliliter (mL) within 56 days.
  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
  • Current enrolment or past participation within the last 30 days or 5 half-lives, whichever is longer, before signing of consent in any other clinical study involving an study intervention or any other type of medical research.
  • Current enrolment or past participation in this clinical study.
  • Positive (HIV) antibody test.
  • Presence of surface antigen (HbsAg) at screening or within 3 months prior to first dose of study intervention.
  • antibody test result at screening or within 3 months prior to first dose of study intervention.
  • A positive confirmation of Coronavirus disease 2019 (COVID-19) infection, or high clinical index of suspicion for COVID-19.
  • The participant, in the judgment of the investigator, would not be able or willing to comply with the protocol or complete the study.
  • Regular alcohol consumption within 6 months prior to the study. An average weekly intake of >14 units for males or females. One unit is equivalent to approximately to 8 g of alcohol: a half-pint (approximately [\~]240 mL) of beer, one glass (125 mL) of wine or one (25 mL) measure of spirits.
  • Positive smoke breathalyzer indicative of smoking history at screening and each in-house admission to the clinical research unit or regular use of tobacco or nicotine-containing products (i.e., nicotine patches or vaporizing devices) within 3 months prior to screening.
  • Regular use of combustible tobacco products, and non-combustible nicotine delivery systems, inclusive of cigarettes, cigars, pipes, and materials used to "vape".
  • Any history of substance abuse or a positive urine test for drugs of abuse/ alcohol breath screen at screening or admission.
  • Known to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
  • for MDZ (i.e., Hypersensitivity to the active substance, benzodiazepines or to any of the , myasthenia gravis, respiratory insufficiency, sleep apnea syndrome, severe hepatic impairment).
  • Use of any products intended to treat medical conditions that are not approved by the governing health authority in a given country or region (for example, herbal medicine, health supplements, traditional medicine, homeopathic remedies, etc.).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    GSK3882347 and MDZ

    Period 1: Participants will receive MDZ on Day 1. Period 2: Participants will receive 14-days of repeat dosing of GSK3882347 Followed by one dose of MDZ co-administered with GSK3882347 on Day 15.

    Drug: Midazolam · Drug: GSK3882347

Interventions

  • DrugMidazolam

    Midazolam will be administered.

  • GSK3882347 will be administered.

06

What researchers measure

Primary outcomes

  1. Period 1: Area under the curve from time zero to 24 hours (AUC [0-24]) for plasma concentration of MDZ

    Time frame: Up to 24 hours

  2. Period 1: AUC (0-24) for plasma concentration of 1-hydroxy-MDZ

    Time frame: Up to 24 hours

  3. Period 2: AUC (0-24) for plasma concentration of MDZ

    Time frame: Up to 24 hours

  4. Period 2: AUC (0-24) for plasma concentration of 1-hydroxy-MDZ

    Time frame: Up to 24 hours

  5. Period 1: AUC from time zero to last time of quantifiable concentration (AUC [0-tau]) for plasma concentration of MDZ

    Time frame: Up to Day 2

  6. Period 1: AUC (0-tau) for plasma concentration of 1-hydroxy-MDZ

    Time frame: Up to Day 2

  7. Period 2: AUC (0-tau) for plasma concentration of MDZ

    Time frame: Up to Day 15

  8. Period 2: AUC (0-tau) for plasma concentration of 1-hydroxy-MDZ

    Time frame: Up to Day 15

  9. Period 1: AUC from time zero extrapolated to infinite time (AUC [0-inf]) for plasma concentration of MDZ

    Time frame: Up to Day 2

  10. Period 1: AUC (0-inf) for plasma concentration of 1-hydroxy-MDZ

    Time frame: Up to Day 2

  11. Period 2: AUC (0-inf) for plasma concentration of MDZ

    Time frame: Up to Day 15

  12. Period 2: AUC (0-inf) for plasma concentration of 1-hydroxy-MDZ

    Time frame: Up to Day 15

  13. Period 1: Maximum plasma concentration (Cmax) of MDZ

    Time frame: Up to Day 2

  14. Period 1: Cmax of 1-hydroxy-MDZ

    Time frame: Up to Day 2

  15. Period 2: Cmax of MDZ

    Time frame: Up to Day 15

  16. Period 2: Cmax of 1-hydroxy-MDZ

    Time frame: Up to Day 15

  17. Period 1: Time to Cmax (Tmax) of MDZ

    Time frame: Up to Day 2

  18. Period 1: Tmax of 1-hydroxy-MDZ

    Time frame: Up to Day 2

  19. Period 2: Tmax of MDZ

    Time frame: Up to Day 15

  20. Period 2: Tmax of 1-hydroxy-MDZ

    Time frame: Up to Day 15

  21. Period 1: Time lag before observation of measurable concentrations (Tlag) of MDZ

    Time frame: Up to Day 2

  22. Period 1: Tlag of 1-hydroxy-MDZ

    Time frame: Up to Day 2

  23. Period 2: Tlag of MDZ

    Time frame: Up to Day 15

  24. Period 2: Tlag of 1-hydroxy-MDZ

    Time frame: Up to Day 15

  25. Period 1: Time to half-life (T1/2) of MDZ

    Time frame: Up to Day 2

  26. Period 1: T1/2 of 1-hydroxy-MDZ

    Time frame: Up to Day 2

  27. Period 2: T1/2 of MDZ

    Time frame: Up to Day 15

  28. Period 2: T1/2 of 1-hydroxy-MDZ

    Time frame: Up to Day 15

Secondary outcomes

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Up to Day 15

  2. Number of participants with clinically significant changes in hematology laboratory values

    Time frame: Up to Day 15

  3. Number of participants with clinically significant changes in chemistry laboratory values

    Time frame: Up to Day 15

  4. Number of participants with clinically significant changes in urinalysis laboratory values

    Time frame: Up to Day 15

  5. Number of participants with clinically significant changes in vital sign values

    Time frame: Up to Day 15

  6. Number of participants with clinically significant changes in 12-lead electrocardiogram (ECG) readings

    Time frame: Up to Day 15

  7. AUC (0-24) for plasma concentration of GSK3882347

    Time frame: Up to 24 hours

  8. Plasma concentrations over the dosing interval tau (Ctau) of GSK3882347

    Time frame: Up to Day 15

  9. Oral clearance (CL/F) of GSK3882347

    Time frame: Up to Day 15

  10. Volume of distribution/ Bioavailability (Vd/F) of GSK3882347

    Time frame: Up to Day 15

  11. Mean residence time (MRT) of GSK3882347

    Time frame: Up to Day 15

  12. AUC(0-inf) for single dose of GSK3882347

    Time frame: Up to Day 2

  13. Cmax for single dose of GSK3882347

    Time frame: Up to Day 2

  14. AUC(0-tau) for repeat dose of GSK3882347

    Time frame: Up to Day 15

  15. Cmax for repeat dose of GSK3882347

    Time frame: Up to Day 15

  16. Accumulation ratio (Ro) using AUC (0-tau) for repeat dose of GSK3882347

    Time frame: Up to Day 15

  17. Time invariance using AUC(0-tau) (repeat dose) of GSK3882347

    Time frame: Up to Day 15

  18. Time invariance using AUC(0-inf) (single dose) of GSK3882347

    Time frame: Up to Day 2

  19. Achievement of steady state of GSK3882347

    Time frame: Up to Day 15

07

Study locations

1 site
  • GSK Investigational Site
    Cambridge, CB2 0GG, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Aug 2024, 16 months.

Of 16 phase 1 interventional studies under Urinary Tract Infections, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 16 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Mar 8, 2023
StartActual
Apr 11, 2023
Primary completionActual
Aug 13, 2024
CompletionActual
Aug 20, 2024
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05760261
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 8, 2023
Start date
Apr 11, 2023
Primary completion
Aug 13, 2024
Completion
Aug 20, 2024
Last update
Jan 16, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK3882347

Start the discussion